|Treatments:||Chemotherapy, Radiation, Surgery||Hospital:||Universitat Heidelberg|
Patients: This phase II study involved 36 patients with advanced, non-metastatic rectal cancer. Of these, 33 had newly diagnosed rectal adenocarcinoma and 3 a local recurrence at the anastomotic site. None had prior pelvic radiotherapy. The median age was 62 years, ranging from 36-82 years. 27 were men and 9 were women.
Treatment: Patients were given radiotherapy and the chemotherapy drugs capecitabine and irinotecan. After completion of radiation and chemotherapy, surgery was performed.
Toxicity: Two instances of Grade 4 leucocytopenia were reported. Other toxicities included anemia, nausea/vomiting, diarrhea, proctitis, abnormal liver laboratory results, dermatitis, and fatigue and were mostly Grades 1 and 2. Two patients died in the postoperative course from septic complications.
Results: Considering all patients (n=36) actuarial calculated overall survival is 83% at 2 years (patients at risk n=23), and 78% at 2.5 years (patients at risk n=15).
Correspondence: Dr. R-D Hofheinz